A Phase 1, Multicenter, Open-Label Study of CC-95266 in Subjects With Relapsed and/or Refractory Multiple Myeloma

The purpose of this study is to evaluate the safety and preliminary efficacy of CC-95266 in participants with relapsed and/or refractory multiple myeloma (R/R MM).


Juno Therapeutics, a Subsidiary of Celgene

Status of enrollment

Accepting new patients

Ages Eligible for Study

For adults ages 18 years and up

Genders Eligible for Study

Females and Males

Disease indication

Multiple Myeloma

Principal Investigator

Sandy Wong, MD


Apoorva Indraghanty

[email protected]

Additional study eligibility details can be found at UCSF Clinical Trials.